Kairos Pharma, Ltd.(KAPA) - 2025 Q4 - Annual Report

Drug Development Pipeline - The company has a pipeline of seven drug candidates, including ENV 105 and ENV 205, targeting significant unmet needs in prostate and lung cancer markets, with the global prostate cancer therapeutics market valued at USD 7.9 billion and EGFR mutant non-small cell lung cancer at USD 1.7 billion[25]. - ENV 105 has shown a clinical benefit rate of 62% in a Phase 2 trial involving heavily pre-treated prostate cancer patients, indicating disease stabilization or regression[25]. - The Phase 2 trial for ENV 105 is being conducted at multiple centers, including Cedars-Sinai, University of Utah, and City of Hope, focusing on patients resistant to standard hormone therapies[31]. - The company initiated three clinical trials in the fall of 2023 for KROS 201 and ENV 105, with ENV 105 targeting both cancer cells and their supportive non-cancer environment to address resistance mechanisms[24]. - KROS 101, a small molecule targeting the GITR ligand, is in pre-IND studies and aims to enhance the antitumor immune response by depleting regulatory T cells[39]. - ENV 205 is designed to target elevated mitochondrial DNA in circulation, which is associated with chemotherapy resistance and aims to restore chemotherapy sensitivity while reducing side effects[33]. - The company is developing KROS 102, KROS 301, and KROS 401, which target various mechanisms of immune suppression at the tumor site[32]. - KROS 201 is an activated T cell therapy targeting glioblastoma, with the market for T cell therapy expected to grow from $4.9 billion in 2021 to $20.8 billion by 2030, reflecting a CAGR of 20.4%[62]. - ENV 105 is in a Phase 2 clinical trial for prostate cancer patients resistant to androgen-targeted therapy, with a potential market of $9 billion for a six-month dose in the U.S. alone[58]. - ENV 205 has shown promise in preclinical studies for limiting chemotherapy-resistant prostate cancer, with the chemotherapy market for docetaxel projected to grow from $137 billion in 2024 to $329 billion by 2033[55]. - KROS 301 is in active preclinical development, targeting the NF-kB pathway, with the global small-molecule cancer therapies market valued at $175.3 billion in 2021[63]. - KROS 401 is a cyclic peptide in preclinical development, with the global peptide therapeutics market size estimated at $117.3 billion in 2024, expected to grow at a CAGR of 10.77%[64]. - The global immune checkpoint inhibitor market size was $47.4 billion in 2023 and is anticipated to reach $189.1 billion by 2032, with a CAGR of 16.7% from 2024 to 2032[61]. - ENV 205 is positioned to address cachexia, a condition affecting 50% of cancer patients, with the specific cancer cachexia therapeutics market projected to grow from over $2 billion in 2022 to over $4 billion by 2032[65]. Clinical Trials and Regulatory Challenges - The company aims to develop innovative therapeutics targeting drug resistance and immune suppression in cancer treatment, with a focus on advancing its clinical pipeline[67]. - The company plans to complete enrollment in a Phase 2 trial of ENV 105 for prostate cancer and a Phase 1 trial for non-small cell lung cancer patients on Tagrisso[67]. - The time required to obtain regulatory approval is unpredictable and typically takes many years, influenced by various factors including the discretion of regulatory authorities and government funding levels[130]. - The company has not submitted a marketing application for any product candidates in any country or region, which is a lengthy and uncertain process requiring extensive data to establish safety and efficacy[133]. - Only a small percentage of drugs in development successfully complete the FDA approval process and are commercialized, posing a significant risk to the company's business and financial condition[134]. - Even if regulatory approval is obtained, it may be contingent on the performance of additional costly clinical trials, which could limit the approved indications or patient populations[145]. - The company relies on third-party contract research organizations for regulatory application support, which may introduce additional risks due to limited experience in this area[129]. - Regulatory approval processes may change during clinical development, impacting the ability to commercialize products in a timely manner[131]. - The company must demonstrate that its product candidates are safe and effective, which requires extensive preclinical and clinical studies that can be costly and time-consuming[139]. - Delays in clinical trials can occur due to various factors, including regulatory requirements, patient recruitment challenges, and unforeseen safety issues[141]. - The company faces significant risks related to the potential for negative clinical trial results, which could prevent obtaining regulatory approval or achieving market acceptance[138]. - Delays in clinical trials could harm the commercial prospects of product candidates and increase costs, potentially allowing competitors to market their products first[147]. - Future regulations from authorities like the FDA may increase the time and cost required for clinical trials, impacting the ability to obtain marketing approvals[148]. - The company has limited experience in designing and implementing clinical trials, which could lead to increased costs and delays in obtaining regulatory approvals[156]. - Serious adverse events (SAEs) or undesirable side effects identified during development could lead to the discontinuation of clinical programs or limitations on product use, affecting commercial potential[150]. - Positive results from early clinical trials may not predict future outcomes, and there is a high failure rate for drugs in clinical development[154]. Financial and Operational Considerations - The company has incurred significant losses since inception and expects to continue incurring losses over the next several years, with no products approved for commercial sale[118]. - The company requires substantial additional funding to meet financial needs and pursue business objectives, with future capital requirements dependent on various factors[119]. - The company has limited operating history, making it difficult to evaluate its prospects for achieving business objectives and commercial success[123]. - The company may face dilution of stockholder ownership if additional capital is raised through equity offerings or debt financings[121]. - The company is committed to employee development, offering competitive compensation and benefits to attract and retain skilled personnel[112]. - The company lacks a sales or marketing infrastructure and limited experience in the sale, marketing, or distribution of pharmaceutical products[200]. - Establishing sales, marketing, and distribution capabilities will require substantial resources and could delay product launches[200]. - Market acceptance of approved product candidates will depend on various factors, including the size of the target market[199]. - Coverage and adequate reimbursement from third-party payors are critical for the commercial success of any product candidates[203]. Patent and Intellectual Property - The company holds multiple patents related to cancer treatment, including compositions and methods for treating cancer and autoimmune diseases, with expiration dates ranging from 2037 to 2040[91][92][93]. - The patent for "Sensitization of Tumors to Therapies through Endoglin Antagonism" is currently in application status in Australia and Canada, with a protection date until June 14, 2037[91][92]. - The company holds a patent for "Method of Generating Activated T Cells for Cancer Therapy," which is set to expire on August 10, 2040 in Canada[91]. - The patent portfolio includes compositions for treating diseases by depletion of mitochondrial or genomic DNA from circulation, with a protection date until November 25, 2040 in Canada[91]. - The company has secured patents in multiple jurisdictions, including China, Europe, and Japan, for various cancer treatment methods and compositions[92][93]. - The patent for "Antibody Formulations and Uses Thereof" is granted in India and Japan, with an expiration date of September 5, 2033[93]. - The company has a granted patent for treating fibrosis, which is applicable in France, Germany, Switzerland, and the United Kingdom, expiring on September 18, 2035[93]. - The patent for "Compositions and Methods for Treating Cancer and Autoimmune Diseases" is granted in Japan, with a protection date until August 8, 2039[93]. - The company is actively pursuing new technologies and methods for cancer treatment, as evidenced by its extensive patent applications and granted patents[91][92][93]. - The company’s patent strategy indicates a strong focus on innovative cancer therapies, positioning it well for future market opportunities[91][92][93]. Acquisitions and Corporate Structure - The company acquired Enviro Therapeutics, Inc. in June 2021, enhancing its pipeline with advanced drug candidates in Phase 1 and Phase 2 trials[21]. - Kairos Pharma conducted a 1-for-2.5 reverse stock split on May 10, 2023, resulting in 10,334,357 shares of common stock outstanding[98]. - The company acquired AcTcell Biopharma, issuing 5,045,000 shares for all outstanding shares of AcTcell[99]. - The acquisition of AcTcell was treated as a transaction under common control, recognizing the historical cost basis of AcTcell's assets and liabilities[100]. - Kairos acquired Enviro in a share exchange, issuing 6,000,000 shares of restricted common stock, representing approximately 20% of the outstanding shares on a fully diluted basis[102]. - Following the Enviro-Kairos share exchange, Kairos had approximately 19,825,957 shares of common stock issued and outstanding on a fully diluted basis[103]. - Effective April 17, 2025, Kairos assumed all responsibilities and liabilities of Enviro under existing agreements, leading to Enviro's dissolution[104]. Market and Economic Factors - The global cancer drug spending was valued at approximately $232 billion in 2024 and is expected to reach $532 billion by 2031, driven by targeted therapies and immuno-oncology[56]. - The healthcare industry's trend towards cost containment may impact the demand and pricing of drugs, affecting commercialization efforts[205]. - The company faces risks associated with international marketing, including differing regulatory requirements and potential economic instability in foreign markets[212]. - The company is exposed to product liability claims that could result in substantial liabilities and limit commercialization of its products[208]. - The company may not be able to obtain adequate product liability insurance coverage, which could adversely affect its operations and share price[209]. - The reliance on single-sourced third parties for clinical trials and manufacturing may lead to delays if those parties fail to perform satisfactorily[215]. - The company must navigate various risks related to compliance with healthcare laws and regulations, which could result in significant penalties and reputational harm[214].